| New from NCI |
| Chemo Benefits Women at High Risk of Breast Cancer Recurrence |
 |
|
An analysis from the TAILORx clinical trial shows which women with early-stage breast cancer are most likely to benefit from chemotherapy and hormone therapy, rather than hormone therapy alone. |
| Improving Multiple Myeloma CAR T-Cell Therapy |
 |
|
Results from a new study suggest a way to improve CAR T-cell therapy for multiple myeloma. The approach relies on a class of drugs that have been studied to treat Alzheimer disease. |
Opportunities in Cancer Research: The Immune System and Microbiome
Cancer immunotherapy harnesses a patient’s own immune system to recognize and destroy cancer cells. Researchers are exploring how to expand the types of immune cells that can be used for immunotherapy. Learn more in this chapter of the NCI Annual Plan & Budget Proposal for Fiscal Year 2021. |
Immunotherapy Plus Chemotherapy Improves Survival in Small Cell Lung Cancer
Small cell lung cancer is usually very hard to treat. Learn more about this cancer and the trial that shows that adding an immunotherapy drug to chemotherapy can help improve how long people newly diagnosed with small cell lung cancer live. |
| PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer |
 |
|
Results from three new clinical trials show that drugs known as PARP inhibitors might benefit women who are newly diagnosed with advanced ovarian cancer. Learn more about each of these trials. |
T-Cell Transfer Therapy
T-cell transfer therapy is a type of immunotherapy that makes your own immune cells better able to attack cancer. Learn how this treatment works, the cancers that are treated with it, and side effects it may cause.
|
| PDQ Cancer Information Summary Updates |
Cardiopulmonary Syndromes
Our PDQ summary on cardiopulmonary syndromes has had a major revision. It includes updated information on the causes, diagnosis, and treatment options for many cancer-related cardiopulmonary syndromes. |
